Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine, and Cytarabine With and Without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma.

Next Previous
Trial Profile

Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine, and Cytarabine With and Without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary) ; Cytarabine; Methotrexate; Procarbazine; Vincristine
  • Indications B-cell lymphoma; CNS cancer; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use

Most Recent Events

  • 23 May 2022 Status changed from active, no longer recruiting to completed.
  • 31 May 2020 Primary endpoint (Progression free survival (PFS) defined as the interval from randomization to progression or death, whichever occurs first) has been met, as per Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
  • 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top